Duvelisib was the 2nd PI3K inhibitor permitted from the FDA, also based on a stage III randomized demo.130 The efficacy and basic safety profile from the drug look similar with All those of idelalisib, if not a bit beneficial. Concerning choice BTK inhibitors, there are lots of products in advancement, but only acalabrutinib is permitted by the FDA